Satellos Bioscience Inc. Cash Flow Conversion Efficiency

Latest as of June 2026: -0.131x

Satellos Bioscience Inc. cash flow conversion efficiency. Based on the latest financial reports, Satellos Bioscience Inc. (MSCL) has a cash flow conversion efficiency ratio of -0.131x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-7.83 Million ≈ $-5.66 Million USD) by net assets (CA$59.81 Million ≈ $43.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Satellos Bioscience Inc. (2007–2025)

Cash flow conversion efficiency of Satellos Bioscience Inc. from 2007 to 2025. This chart illustrates how Satellos Bioscience Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View MSCL stock price and chart for real-time trading data and today's change.

Satellos Bioscience Inc. Cash Flow Conversion Ratio Explained

Satellos Bioscience Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Satellos Bioscience Inc. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Satellos Bioscience Inc. ranked by their cash flow conversion efficiency. Also see market cap of Satellos Bioscience Inc. for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
King Polytechnic Engineering Co Ltd
TWO:6122
0.110x
Bitcoin Group SE
XETRA:ADE
0.008x
CYGNUS Metals Ltd
AU:CY5
-0.033x
LG Household & Healthcare Ltd Pref
KO:051905
0.029x
Capacit'e Infraprojects Limited
NSE:CAPACITE
0.028x
Land General Bhd
KLSE:3174
0.065x
Baozun Inc
NASDAQ:BZUN
0.000x
Tucows Inc.
TO:TC
-0.019x

Annual Cash Flow Conversion Efficiency for Satellos Bioscience Inc. (2007–2025)

The table below shows the annual cash flow conversion efficiency of Satellos Bioscience Inc. from 2007 to 2025. Review MSCL free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CA$27.73 Million
≈ $20.06 Million
CA$-24.01 Million
≈ $-17.37 Million
-0.866x -135.23%
2024-12-31 CA$67.86 Million
≈ $49.09 Million
CA$-24.98 Million
≈ $-18.07 Million
-0.368x -3.83%
2023-12-31 CA$40.67 Million
≈ $29.42 Million
CA$-14.42 Million
≈ $-10.43 Million
-0.354x +78.84%
2022-12-31 CA$3.37 Million
≈ $2.44 Million
CA$-5.64 Million
≈ $-4.08 Million
-1.675x -248.79%
2021-12-31 CA$10.48 Million
≈ $7.58 Million
CA$-5.03 Million
≈ $-3.64 Million
-0.480x -105.32%
2020-12-31 CA$-183.84K
≈ $-132.98K
CA$-1.66 Million
≈ $-1.20 Million
9.030x +291.71%
2019-12-31 CA$408.57K
≈ $295.56K
CA$-1.92 Million
≈ $-1.39 Million
-4.710x -366.32%
2018-12-31 CA$-624.38K
≈ $-451.67K
CA$-1.10 Million
≈ $-798.83K
1.769x +407.07%
2016-12-31 CA$2.31 Million
≈ $1.67 Million
CA$-1.33 Million
≈ $-963.36K
-0.576x +29.65%
2015-12-31 CA$3.78 Million
≈ $2.74 Million
CA$-3.10 Million
≈ $-2.24 Million
-0.819x -59.16%
2014-12-31 CA$5.51 Million
≈ $3.99 Million
CA$-2.84 Million
≈ $-2.05 Million
-0.514x +82.25%
2013-12-31 CA$1.30 Million
≈ $940.12K
CA$-3.77 Million
≈ $-2.72 Million
-2.898x -115.11%
2012-12-31 CA$2.05 Million
≈ $1.48 Million
CA$-2.76 Million
≈ $-2.00 Million
-1.347x -87.28%
2011-12-31 CA$2.69 Million
≈ $1.95 Million
CA$-1.93 Million
≈ $-1.40 Million
-0.719x +35.67%
2010-12-31 CA$2.38 Million
≈ $1.73 Million
CA$-2.67 Million
≈ $-1.93 Million
-1.118x -126.79%
2009-12-31 CA$4.29 Million
≈ $3.11 Million
CA$-2.12 Million
≈ $-1.53 Million
-0.493x +78.84%
2008-12-31 CA$1.03 Million
≈ $745.64K
CA$-2.40 Million
≈ $-1.74 Million
-2.330x -48.35%
2007-12-31 CA$2.49 Million
≈ $1.80 Million
CA$-3.91 Million
≈ $-2.83 Million
-1.570x --

About Satellos Bioscience Inc.

TO:MSCL Canada Biotechnology
Market Cap
$138.13 Million
CA$190.95 Million CAD
Market Cap Rank
#17768 Global
#565 in Canada
Share Price
CA$9.00
Change (1 day)
-0.55%
52-Week Range
CA$0.65 - CA$17.85
All Time High
CA$17.85
About

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small m… Read more